

08/812,508

-22-

5117-C1-01-MG

REMARKS*Claim disposition*

Claims 73-88 are pending in the application.

Claims 73 to 75, 78, 79, 84, 87, and 88 are cancelled without disclaimer or prejudice, in order to facilitate prosecution and allowance. Applicant hereby reserves the right to file continuing applications or take any other such appropriate measure to prosecute the cancelled subject matter.

New claims 89 to 92 are added.

Claims 76, 77, 80 to 83, 85, 86, and 89-92 will be pending in the application upon entry of this amendment.

The rejection under 35 U.S.C. § 112, first paragraph, should be withdrawn

Claims 79, 84, 87, and 88 were rejected under 35 U.S.C. § 112, first paragraph. This rejection is obviated by cancellation of said claims. Therefore, Applicant respectfully requests that the rejections under 35 U.S.C. § 112, first paragraph, be withdrawn.

The rejection under 35 U.S.C. § 102(b) should be withdrawn

Claims 73 to 75, 78 and 88 were rejected under 35 U.S.C. § 102 (b). This rejection is obviated by cancellation of said claims. Therefore, Applicant respectfully requests that the rejections under 35 U.S.C. § 102(b) be withdrawn.

The rejection under 35 U.S.C. § 112, second paragraph, should be withdrawn

Claims 74 and 79 were rejected under 35 U.S.C. § 112, second paragraph. This rejection is obviated by cancellation of said claims. Therefore, Applicant respectfully requests that the rejections under 35 U.S.C. § 112, second paragraph, be withdrawn.

New Claims

New claims 89 and 90 are directed to pharmaceutically acceptable salts of the compounds of claims 76 and 77, respectively. New Claims 91 to 92 are directed to pharmaceutical compositions comprising the compounds of claims 76 and 77, respectively.

08/812,508

-23-

5117-C1-01-MG

These new claims are fully supported by the specification as originally filed. For example, see pages 39-41 and 78-81 of the specification.


Upon entry of the present amendment, the Applicants submit that this application is now in condition for allowance, which allowance is respectfully solicited.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at 734-622-2658.

Respectfully submitted,

Dated: Nov. 4, 2004



Mehdi Ganjeizadeh
Reg. No. 47,585
Warner-Lambert Company LLC
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-3831
Fax (734) 622-2928